| Model Number: | W025 |
|---|---|
| Brand Name: | [Window Title] |
| Grade: | Cosmetic Grade, Feed Grade, Medicine |
| Place of Origin: | China (Mainland) |
| Packaging: | Bottle,Can,Drum,Glass Container,Vacuum Packed,1kg/bag25kg/druminner with vacuum packing or as the customer's requi,, |
| Extraction Type: | Solvent Extraction |
| Part: | Leaf |
| Form: | Powder |
| Type: | Herbal Extract |
| Variety: | Paclitaxel |
| Appearance: | white powder |
Quick Details
Specifications
Introduction:
1 Natrual Paclitaxel 99.5% HPLC
2 Standard: USP 32
3 Appearance: white crysaline powder
4 Mole formular: C47H51NO14
2 CAS:33069-62-5 / 33069-62-5
4 melting point: 213-216 degree
5 GMP certified manufacturer , Rich Exporting Experience
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it 'taxol'. When it was developed commercially by BristolMyers Squibb (BMS) the generic name was changed to 'paclitaxel' and the BMS compound is sold under the trademark 'TAXOL'. In this formulation, paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.
Specifications:
|
Tests |
Standards |
Results |
|
|
Appearance |
white powder |
Wcrystalline powder.hite, |
|
|
Identification |
A:IR absorption |
Complies |
Complies |
|
B:UV absorption |
Complies |
Complies |
|
|
C:TLC |
Complies |
Complies |
|
|
Melting point |
168~172°C |
169.0~170.9°C |
|
|
Water |
Not more than0.5% |
0.08% |
|
|
Related substance |
ImpurityJ(chloroacetanilide)not more than 10 ppm |
2ppm |
|
|
Impurity K(4-aminophenol)not more than 50 ppm |
15 ppm |
||
|
Impurity F(4-nitrophenol)not more than 0.05% |
Not detected |
||
|
any other impurity not more than 0.05% |
0.01% |
||
|
Total of other impurities not more than 0.1% |
0.02% |
||
|
Residue on ignition |
Not more than 0.1% |
0.05% |
|
|
Chloride |
Not more than 0.014% |
Less than 0.014% |
|
|
Sulfate |
Not more than 0.02% |
Less than 0.02% |
|
|
Sulfide |
Conforms |
Conforms |
|
|
Heavy metals |
Not more than 0.001% |
Less than 0.001% |
|
|
Free p-aminophenol |
Not more than 0.005% |
Less than 0.005% |
|
|
Limit of P-chloroacetanilide |
Not more than 0.001% |
Less than 0.001% |
|
|
Readily carbonizable substances |
Conforms |
Conforms |
|
|
Residual solvents |
Residual content of acetic acid is limited by the test of loss on dryingnot more than0.5% |
0.08% |
|
|
Assay(anhydrous basis) |
99.0~101.0% |
99.6% |
|
|
Conclusion: Complies with USP34/ BP2011 |
|||
Function:
Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis. Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes .